Cancer-associated thrombosis: what is new?

Area of Science:

• Oncology
• Hematology
• Clinical Pharmacology

Background:

• Cancer-associated thrombosis (CAT) is increasingly recognized as a chronic condition due to improved life expectancy in cancer patients.
• Patients with CAT are particularly vulnerable, facing high risks of complications despite anticoagulant therapy.

Purpose of the Study:

• To review current challenges and emerging strategies in managing cancer-associated thrombosis.
• To highlight the need for personalized anticoagulation and risk stratification in CAT patients.

Main Methods:

• Review of recent clinical practice issues and therapeutic advancements in CAT.
• Analysis of prediction scores for venous thromboembolism recurrence and bleeding risk.
• Evaluation of novel anticoagulant strategies, including anti-XI agents.

Main Results:

• Personalization of anticoagulation therapy is crucial for optimizing the benefit-risk ratio in CAT.
• Development and investigation of prediction scores aid in identifying high-risk patients.
• Extended treatment durations and novel agents like anti-XI inhibitors are under evaluation.

Conclusions:

• Improved prognosis in CAT necessitates refined therapeutic strategies to balance efficacy and safety.
• New approaches aim to mitigate the dual risks of venous thromboembolic recurrence and hemorrhagic complications in fragile cancer patients.